These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38389038)

  • 21. DOT or SAT for Rifampicin-resistant tuberculosis? A non-randomized comparison in a high HIV-prevalence setting.
    Mohr E; Daniels J; Beko B; Isaakidis P; Cox V; Steele SJ; Muller O; Snyman L; De Azevedo V; Shroufi A; Trivino Duran L; Hughes J
    PLoS One; 2017; 12(5):e0178054. PubMed ID: 28542441
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rifampicin mono-resistance in Mycobacterium tuberculosis in KwaZulu-Natal, South Africa: a significant phenomenon in a high prevalence TB-HIV region.
    Coovadia YM; Mahomed S; Pillay M; Werner L; Mlisana K
    PLoS One; 2013; 8(11):e77712. PubMed ID: 24223122
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factors associated with unfavourable treatment outcomes among people with rifampicin-resistant tuberculosis in Armenia, 2014-2017.
    Khachatryan L; Grigoryan R; Dadu A; Kumar AMV; Akopyan K; Dumchev K; Harutyunyan H; Matteelli A
    Monaldi Arch Chest Dis; 2021 Jan; 91(1):. PubMed ID: 33470086
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Decentralized, Integrated Treatment of RR/MDR-TB and HIV Using a Bedaquiline-Based, Short-Course Regimen Is Effective and Associated With Improved HIV Disease Control.
    Govender T; Jham MA; Zhang JC; Pillay S; Pak Y; Pillay P; Furin J; Malenfant J; Murphy RA
    J Acquir Immune Defic Syndr; 2023 Apr; 92(5):385-392. PubMed ID: 36729541
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High rates of multidrug-resistant and rifampicin-resistant tuberculosis among re-treatment cases: where do they come from?
    Ragonnet R; Trauer JM; Denholm JT; Marais BJ; McBryde ES
    BMC Infect Dis; 2017 Jan; 17(1):36. PubMed ID: 28061832
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost per patient of treatment for rifampicin-resistant tuberculosis in a community-based programme in Khayelitsha, South Africa.
    Cox H; Ramma L; Wilkinson L; Azevedo V; Sinanovic E
    Trop Med Int Health; 2015 Oct; 20(10):1337-45. PubMed ID: 25975868
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Organisation of care for people receiving drug-resistant tuberculosis treatment in South Africa: a mixed methods study.
    Dickson L; Le Roux SR; Mitrani L; Hill J; Jassat W; Cox H; Mlisana K; Black J; Loveday M; Grant A; Kielmann K; Ndjeka N; Moshabela M; Nicol M
    BMJ Open; 2023 Nov; 13(11):e067121. PubMed ID: 37977868
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatocellular Injury in Children Treated for Rifampicin-resistant Tuberculosis: Incidence, Etiology and Outcome.
    Duvenhage J; Draper HR; Garcia-Prats AJ; Winckler J; Hesseling AC; Schaaf HS
    Pediatr Infect Dis J; 2022 Dec; 41(12):953-958. PubMed ID: 36102699
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Whole-Genome Sequencing Has the Potential To Improve Treatment for Rifampicin-Resistant Tuberculosis in High-Burden Settings: a Retrospective Cohort Study.
    Cox H; Goig GA; Salaam-Dreyer Z; Dippenaar A; Reuter A; Mohr-Holland E; Daniels J; Cudahy PGT; Nicol MP; Borrell S; Reinhard M; Doetsch A; Beisel C; Gagneux S; Warren RM; Furin J
    J Clin Microbiol; 2022 Mar; 60(3):e0236221. PubMed ID: 35170980
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High rates of death and loss to follow-up by 12 months of rifampicin resistant TB treatment in South Africa.
    Hirasen K; Berhanu R; Evans D; Rosen S; Sanne I; Long L
    PLoS One; 2018; 13(10):e0205463. PubMed ID: 30300403
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk factors for unfavourable treatment outcomes among rifampicin-resistant tuberculosis patients in Tajikistan.
    Makhmudova M; Maxsumova Z; Rajabzoda A; Makhmadov A; van den Hof S; Mirtskhulava V
    Int J Tuberc Lung Dis; 2019 Mar; 23(3):331-336. PubMed ID: 30871664
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence and factors associated with multidrug/rifampicin resistant tuberculosis among suspected drug resistant tuberculosis patients in Botswana.
    Tembo BP; Malangu NG
    BMC Infect Dis; 2019 Sep; 19(1):779. PubMed ID: 31492099
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment outcomes and safety in children with rifampicin-resistant TB.
    Lopez-Varela E; Garcia-Prats AJ; Seddon JA; Draper HR; Winckler J; van der Laan L; Palmer M; Burger WA; Schaaf HS; Hesseling AC
    Int J Tuberc Lung Dis; 2022 Feb; 26(2):133-141. PubMed ID: 35086625
    [No Abstract]   [Full Text] [Related]  

  • 34. Rifampicin-resistant tuberculosis patients in Myanmar in 2016: how many are lost on the path to treatment?
    Htet KKK; Soe KT; Kumar AMV; Saw S; Win Maung HM; Myint Z; Khine TMM; Aung ST
    Int J Tuberc Lung Dis; 2018 Apr; 22(4):385-392. PubMed ID: 29562985
    [TBL] [Abstract][Full Text] [Related]  

  • 35. "Take the treatment and be brave": Care experiences of pregnant women with rifampicin-resistant tuberculosis.
    Loveday M; Hlangu S; Furin J
    PLoS One; 2020; 15(12):e0242604. PubMed ID: 33347448
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High rate of successful treatment outcomes among childhood rifampicin/multidrug-resistant tuberculosis in Pakistan: a multicentre retrospective observational analysis.
    Naz F; Ahmad N; Wahid A; Ahmad I; Khan A; Abubakar M; Khan SA; Khan A; Latif A; Ghafoor A
    BMC Infect Dis; 2021 Dec; 21(1):1209. PubMed ID: 34863099
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Factors contributing to the high prevalence of multidrug-resistance/Rifampicin-resistance in patients with tuberculosis: an epidemiological cross sectional and qualitative study from Khabarovsk krai region of Russia.
    Bykov I; Dyachenko O; Ratmanov P; Liu H; Liang L; Wu Q
    BMC Infect Dis; 2022 Jul; 22(1):612. PubMed ID: 35831812
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of rifampicin-resistant TB: programme indicators and care cascade analysis in South Africa.
    De Vos E; Scott L; Voss De Lima Y; Warren RM; Stevens W; Hayes C; da Silva P; Van Rie A
    Int J Tuberc Lung Dis; 2021 Feb; 25(2):134-141. PubMed ID: 33656425
    [No Abstract]   [Full Text] [Related]  

  • 39. Predictors of mortality and treatment success during treatment for rifampicin-resistant tuberculosis within the South African National TB Programme, 2009 to 2011: a cohort analysis of the national case register.
    Schnippel K; Shearer K; Evans D; Berhanu R; Dlamini S; Ndjeka N
    Int J Infect Dis; 2015 Oct; 39():89-94. PubMed ID: 26358856
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Study on the resistance of rifampicin-resistant Mycobacterium tuberculosis to anti-tuberculosis drugs in group A].
    Dai XW; Li CY; Wang NH; Chen SS; Tian LL; Zhao YF; Tao LY; Yang XY; Ding BC; He XX
    Zhonghua Jie He He Hu Xi Za Zhi; 2023 Nov; 46(11):1110-1117. PubMed ID: 37914422
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.